MRUS Jun 2024 30.000 put
| Previous close | 1.6000 |
| Open | 0.2000 |
| Bid | 0.1000 |
| Ask | 0.1500 |
| Strike | 30.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.1500 - 0.2700 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.59k |
Investor's Business DailyWhy Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
Merus stock catapulted to a record high Friday after its experimental regimen for head-and-neck cancer beat expectations in a key study.
BenzingaWhy Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Thursday, Merus N.V. (NASDAQ:MRUS) announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting website. Keytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract presents interim clinical data from a cohort of 26 patients enrolled as of the abstract cutoff date, evaluating the combination in first-line (1L) recurrent/metastatic (r/m) head and neck squa
Barrons.comMerus Clears Wall Street's Bar With Cancer Data
Merus appears to have cleared the bar set by Wall Street for its highly watched cancer-treatment candidate. The company posts an abstract for its head and neck cancer treatment on Thursday, boasting a 60% response rate and one complete response in a pool of 10 evaluable patients. William Blair analysts say in a research note that the early dataset is a clear encouraging sign on the potential treatment's efficacy.
